Press Release (ePRNews.com) - NEGRIL, Jamaica - Nov 15, 2017 - Doc’s Place International, Inc., an international health and wellness resort, is pleased to announce its first international expansion through a strategic relationship with Apollon Formularies Jamaica, Ltd., a Jamaican company specializing in the legal production of medical cannabis-based pharmaceutical products to establish the world’s first Global Center of Excellence for Medical Cannabis Therapy in Negril, Jamaica, for the treatment of patients living in Jamaica, as well as international patients worldwide traveling to Jamaica for physician-administered safe and legal medical cannabis treatments.
Doc’s Place International, Inc. and Apollon Formularies Jamaica, Ltd. believe that all medical cannabis-based pharmaceuticals should be administered under supervision of physicians with special expertise in treating patients with legal medical cannabis products. As such, we have established a medical team of independent physicians licensed to practice medicine in Jamaica and the U.S. who have additional special expertise treating patients with medical cannabis pharmaceuticals. Our medical team includes physicians specializing in neurosurgery, oncology, palliative care, dermatology and family practice.
Stephen D. Barnhill, MD, CEO of Doc’s Place International, Inc. and a director of Apollon Formularies Jamaica, Ltd., stated: “As Hippocrates once said ‘Healing is a matter of time, but it is sometimes also a matter of opportunity.’” Dr. Barnhill continued, “This strategic relationship provides patients worldwide with the ‘opportunity’ to receive world-class medical cannabis treatments provided by licensed physicians with special expertise in treating patients with medical cannabis-based pharmaceuticals in a safe, professional, medical and legal environment.”
This strategic relationship provides patients worldwide with the ‘opportunity’ to receive world-class medical cannabis treatments provided by licensed physicians with special expertise in treating patients with medical cannabis-based pharmaceuticals in a safe, professional, medical and legal environment.
Medical cannabis has been shown to be beneficial in myriad of conditions including Prostate Cancer, Breast Cancer, Brain Cancer, Nausea/Vomiting (chemotherapy), Nausea/Vomiting (sea sickness), Post Traumatic Stress Disorder (PTSD), Chronic Pain, Arthritis, Crohn’s Disease/Ulcerative Colitis, Epilepsy, Glaucoma, HIV, Alzheimer’s Disease, Lupus (SLE), Opioid/Narcotic Rehabilitation, Parkinson’s Disease, Anxiety Disorders and Sleep Disorders.
Anthony Hall, MD, medical director of Doc’s Place International, Inc. and a U.S. board-certified neurosurgeon, stated: “We are very excited about the opening of the world’s first Global Center of Excellence for Medical Cannabis Therapy in Negril, Jamaica, which will provide patients specialized medical care for the myriad of conditions shown to be beneficially treated with medical cannabis pharmaceuticals in a Federally legal environment.”
Herb Fritsche, Ph.D., chief science officer of Doc’s Place International, Inc. and former professor and director of Clinical Chemistry at MD Anderson Cancer Center, stated: “Having the world’s first Global Center of Excellence for Medical Cannabis Therapy gives us the opportunity to do state-of-the-art research and development based on patient outcomes data, create and adapt pharmaceutical formulations, establish accurate therapeutic doses and develop genomic markers to better determine the proper course of treatment for patients being treated by our excellent medical team using Apollon Formularies Jamaica, Ltd.’s award-winning medical cannabis strains and cannabis-based pharmaceutical formulary.“
Breathtaking climate, gorgeously captivating scenery, heartwarming people and an intriguingly unforgettable adventure describe Jamaica. It’s a wonderful place to relax and heal. As such, The Jamaican Ministry of Health recently said they are aiming to attract over 100,000 medical tourists to the island within the next 10 years. Doc’s Place International’s Global Center for Medical Cannabis Therapy aims to be a major contributor to this increase in medical tourists to Jamaica.
Paul Burke, CEO of Apollon Formularies Jamaica, Ltd., stated: “We are very pleased to have a strategic relationship with Doc’s Place International to open the world’s first Global Center of Excellence for Medical Cannabis Therapy in Negril, Jamaica, and to provide legal, state-of-the-art, quality-controlled medical cannabis-based pharmaceuticals to the excellent medical team treating these patients.“
About Doc’s Place International, Inc. – Doc’s Place International is a U.S. corporation established in 2017 to open health and wellness resorts in the U.S. and international locations. These resorts will be state-of-the-art, next-generation master-planned wellness and treatment facilities designed to serve patients obtaining medical treatments in a resort-style environment that enhances the quality of life for those being served. These health and wellness centers will provide facilities to be modeled after treatment centers, spas, resorts and hotels that provide hospitality-oriented services in combination with personal care and well-being services. These Centers will provide a safe, professional, legal and secure environment for both the patients and their families and friends.
About Apollon Formularies Jamaica, Ltd. – Apollon Formularies Jamaica, Limited (“Apollon”) is a Jamaican corporation established in 2016 to be the legal authorized operator for cultivation, pharmaceutical preparation, sale and treatment of patients with medical cannabis as was legalized in Jamaica in April of 2015. In November 2016, Apollon’s medical cannabis farm in Orange Hill, Jamaica, and treatment facility in Negril, Jamaica, successfully passed inspection by the Jamaican Scientific Review Council (SRC) and was approved to begin operations by the Ministry of Science, Energy and Technology. In November 2017, Apollon received additional legal rights to operate in the form of conditional approvals from the Cannabis Licensing Authority (CLA) in Jamaica for Retail (Therapeutic), Processing (Tier 2) and Research and Development.
Apollon has created its own proprietary medical strains called “APM” and “G4H.” The “APM” strain won first place at the High Times Cannabis Cup competition in Jamaica for the Cannabis Indica category, which is the category used to treat many diseases. Apollon Jamaica’s “G4H” strain won first place at the Jamaican Stepping High Festival. These two award-winning strains are the first two of a full line of strains to be developed for treating patients and are currently used to create the current full line of Apollon cannabis-based pharmaceuticals.
About the Global Center of Excellence for Medical Cannabis Therapy – The Global Center of Excellence for Medical Cannabis Therapy in Negril, Jamaica, is a state-of-the-art, next-generation master-planned wellness and treatment facility designed to serve patients seeking medical cannabis-based pharmaceutical treatment by licensed physicians with special expertise in medical cannabis-based pharmaceuticals. The goal is to provide an environment that enhances the quality of life for those being served. The center will be modeled after treatment centers, spas, resorts and hotels that provide hospitality-oriented services in combination with personal care and well-being services. The Center will provide a safe, secure, professional and legal environment for both the patients and their families and friends.
When used in this Press Release hereto, the words “expect,” “estimate,” “may,” “would,” “could,” “expect,” “intend,” “plan,” “project,” “intend,” “anticipate” and similar expressions are intended to identify forward-looking statements regarding events and financial trends that may affect the Company’s future operating results and financial condition. Such statements are “forward-looking statements” as defined by applicable law, including the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause the Company’s actual results and financial condition to differ materially. Such factors include, among others: (i) the sensitivity of the Company’s business to general economic conditions; and (ii) other economic, competitive and governmental factors affecting the Company’s operations, markets and products. The Company undertakes no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events.
Contact: Source :
Doc's Place International, Inc.